Evidence map›Paper›PMID 26815318›Full record

ArticleScientific reports2016

Capture and On-chip analysis of Melanoma Cells Using Tunable Surface Shear forces.

Simon Chang-Hao Tsao, Ramanathan Vaidyanathan, Shuvashis Dey, Laura G Carrascosa, Christopher Christophi, Jonathan Cebon, Muhammad J A Shiddiky, Andreas Behren, Matt Trau

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 8 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Simon Chang-Hao TsaoOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, 3084, Australia.
Ramanathan VaidyanathanCentre for Personalised NanoMedicine, Australian Institute for Bioengineering and Nanotechnology, University of Queensland.
Shuvashis DeyCentre for Personalised NanoMedicine, Australian Institute for Bioengineering and Nanotechnology, University of Queensland.
Laura G CarrascosaCentre for Personalised NanoMedicine, Australian Institute for Bioengineering and Nanotechnology, University of Queensland.
Christopher ChristophiDepartment of Surgery - Austin Health, University of Melbourne, Heidelberg, Victoria, 3084, Australia.
Jonathan CebonOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, 3084, Australia.
Muhammad J A ShiddikyCentre for Personalised NanoMedicine, Australian Institute for Bioengineering and Nanotechnology, University of Queensland.
Andreas BehrenOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, 3084, Australia.
Matt TrauCentre for Personalised NanoMedicine, Australian Institute for Bioengineering and Nanotechnology, University of Queensland.
University of Queensland · AUOlivia Newton-John Cancer Wellness & Research Centre · AUAustin Health · AUUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With new systemic therapies becoming available for metastatic melanoma such as BRAF and PD-1 inhibitors, there is an increasing demand for methods to assist with treatment selection and response monitoring. Quantification and characterisation of circulating melanoma cells (CMCs) has been regarded as an excellent non-invasive candidate but a sensitive and efficient tool to do these is lacking. Herein we demonstrate a microfluidic approach for melanoma cell capture and subsequent on-chip evaluation of BRAF mutation status. Our approach utilizes a recently discovered alternating current electrohydrodynamic (AC-EHD)-induced surface shear forces, referred to as nanoshearing. A key feature of nanoshearing is the ability to agitate fluid to encourage contact with surface-bound antibody for the cell capture whilst removing nonspecific cells from the surface. By adjusting the AC-EHD force to match the binding affinity of antibodies against the melanoma-associated chondroitin sulphate proteoglycan (MCSP), a commonly expressed melanoma antigen, this platform achieved an average recovery of 84.7% from biological samples. Subsequent staining with anti-BRAF(V600E) specific antibody enabled on-chip evaluation of BRAF(V600E) mutation status in melanoma cells. We believe that the ability of nanoshearing-based capture to enumerate melanoma cells and subsequent on-chip characterisation has the potential as a rapid screening tool while making treatment decisions.

Indexed as

Cell SeparationLab-On-A-Chip DevicesAntibodies, NeoplasmAntigens, NeoplasmCell Line, TumorChondroitin Sulfate ProteoglycansHumansMelanomaMutationProto-Oncogene Proteins B-rafAntibodies, NeoplasmAntigens, NeoplasmBRAF protein, humanChondroitin Sulfate ProteoglycansProto-Oncogene Proteins B-raf

Identifiers

PMID26815318
PMCPMC4728558
OpenAlexW2304485350

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.